Published in Am J Surg Pathol on February 01, 2007
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
Ovarian cancer development and metastasis. Am J Pathol (2010) 5.92
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Ovarian cancer. Annu Rev Pathol (2009) 4.92
The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer (2010) 4.06
New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol (2008) 3.26
Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol (2008) 3.22
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 2.81
Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A (2011) 2.71
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol (2008) 2.60
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol (2008) 2.50
The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol (2013) 2.47
The mammalian ovary from genesis to revelation. Endocr Rev (2009) 2.31
The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med (2009) 2.29
Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene (2009) 2.27
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer (2010) 2.13
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res (2007) 2.12
High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A (2012) 2.03
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch (2012) 1.80
Ovarian cancer pathogenesis: a model in evolution. J Oncol (2009) 1.77
The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol (2010) 1.70
Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol (2013) 1.64
Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol (2009) 1.62
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol (2009) 1.54
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 1.53
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle (2010) 1.48
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46
Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol (2010) 1.44
Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement. Hum Reprod (2011) 1.43
Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol (2010) 1.39
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol (2012) 1.34
Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol (2010) 1.32
Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer (2010) 1.30
Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene (2011) 1.29
Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol (2010) 1.27
Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol Oncol (2008) 1.25
Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol (2010) 1.24
Ovarian Cancer Is an Imported Disease: Fact or Fiction? Curr Obstet Gynecol Rep (2012) 1.23
MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One (2009) 1.18
A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol (2014) 1.17
Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle (2012) 1.16
Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol (2011) 1.15
Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol (2012) 1.13
The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention". Clin Obstet Gynecol (2012) 1.13
Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int (2014) 1.11
CA125 in ovarian cancer. Biomark Med (2007) 1.10
Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res (2013) 1.09
Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation. Stem Cells (2012) 1.09
Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med (2009) 1.09
Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol (2013) 1.07
Ovarian cancer screening--current status, future directions. Gynecol Oncol (2013) 1.06
FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol (2015) 1.06
Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. J Pathol (2013) 1.06
Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod (2013) 1.06
Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer (2010) 1.02
Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol (2013) 1.01
Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol (2009) 1.00
Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol (2009) 1.00
Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases. Virchows Arch (2010) 0.99
Molecular-targeted therapies for ovarian cancer: prospects for the future. Int J Clin Oncol (2012) 0.99
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer (2014) 0.99
The hen as a model of ovarian cancer. Nat Rev Cancer (2013) 0.98
Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol (2011) 0.97
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer. Front Oncol (2015) 0.97
An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer. Nat Commun (2015) 0.96
Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: fact or artifact? Int J Cancer (2009) 0.96
Next-Generation Sequencing of Tubal Intraepithelial Carcinomas. JAMA Oncol (2015) 0.96
Fallopian tube correlates of ovarian serous borderline tumors. Am J Surg Pathol (2011) 0.95
Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol (2013) 0.95
Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol (2012) 0.94
Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci (2013) 0.93
Evaluating the progenitor cells of ovarian cancer: analysis of current animal models. BMB Rep (2011) 0.92
The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin. Int J Mol Sci (2013) 0.92
Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update. J Obstet Gynaecol Res (2014) 0.92
Origin of ovarian cancer: molecular profiling. J Obstet Gynaecol India (2013) 0.91
Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci U S A (2016) 0.91
Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. Int J Clin Exp Pathol (2012) 0.91
Epithelial ovarian cancer: An overview. World J Transl Med (2014) 0.91
Ovarian cancer: opportunity for targeted therapy. J Oncol (2011) 0.90
It's Totally Tubular…Riding The New Wave of Ovarian Cancer Research. Cancer Res (2015) 0.90
Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. Int J Gynecol Cancer (2012) 0.89
Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. Diagn Histopathol (Oxf) (2008) 0.89
Mutant p53 expression in fallopian tube epithelium drives cell migration. Int J Cancer (2015) 0.89
Characterization of the immune cell repertoire in the normal fallopian tube. Int J Gynecol Pathol (2014) 0.88
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol (2016) 0.88
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol (2015) 0.87
Carcinomas of Distal Fallopian Tube and Their Association with Tubal Intraepithelial Carcinoma: Do They Share a Common "Precursor" Lesion? Loss of Heterozygosity and Immunohistochemical Analysis Using PAX 2, WT-1, and P53 Markers. ISRN Obstet Gynecol (2010) 0.87
Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes. PLoS One (2013) 0.87
Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene (2012) 0.87
Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer (2016) 0.86
Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin. Int J Cancer (2013) 0.86
Ovary and fimbrial stem cells: biology, niche and cancer origins. Nat Rev Mol Cell Biol (2015) 0.86
The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium. J Pathol (2014) 0.86
CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Mod Pathol (2016) 0.86
Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol (2014) 0.85
An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. Int J Clin Exp Pathol (2011) 0.84
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell (2007) 6.50
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA (2007) 4.33
Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA (2002) 4.32
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res (2005) 3.41
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol (2007) 3.02
Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell (2011) 3.00
Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer (2014) 2.94
Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction. Int J Cancer (2014) 2.74
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol (2008) 2.50
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Gestational trophoblastic disease. Lancet (2010) 2.43
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.43
Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol (2008) 2.42
Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol (2009) 2.40
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Image gently: Ten steps you can take to optimize image quality and lower CT dose for pediatric patients. AJR Am J Roentgenol (2010) 2.36
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell (2002) 2.24
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res (2006) 2.20
Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol (2010) 2.18
The Image Gently campaign: working together to change practice. AJR Am J Roentgenol (2008) 2.16
Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. Int J Gynecol Pathol (2010) 2.16
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry. J Clin Oncol (2011) 2.13
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell (2009) 2.13
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res (2007) 2.12
Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res (2004) 2.05
Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet Gynecol (2003) 2.04
The 'Image Gently' campaign: increasing CT radiation dose awareness through a national education and awareness program. Pediatr Radiol (2008) 2.03
Trimodal spectroscopy for the detection and characterization of cervical precancers in vivo. Am J Obstet Gynecol (2002) 2.02
Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev (2002) 1.97
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol (2002) 1.88
NAD(P)H and collagen as in vivo quantitative fluorescent biomarkers of epithelial precancerous changes. Cancer Res (2002) 1.88
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol (2011) 1.87
Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol (2009) 1.87
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene (2004) 1.82
USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol (2004) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A (2012) 1.81
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol (2007) 1.80
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol (2010) 1.80
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat (2005) 1.73
The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol (2010) 1.70
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
Robotic versus open radical hysterectomy: a comparative study at a single institution. Gynecol Oncol (2008) 1.68
Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res (2009) 1.66
A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol (2011) 1.64
A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A (2012) 1.64
Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol (2009) 1.62
HPV testing. Visible expectations and hidden realities. Am J Clin Pathol (2003) 1.59
PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol (2010) 1.57
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol (2010) 1.54
Eosinophilic dysplasia of the cervix: a newly recognized variant of cervical squamous intraepithelial neoplasia. Am J Surg Pathol (2004) 1.54
Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A (2011) 1.53
Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res (2003) 1.53
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer (2013) 1.52
Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells. Hum Pathol (2005) 1.52
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51